Among them, Dihydroergotamine emerged as the top-ranked candidate, exhibiting the strongest predicted binding affinity to CD72 (−10.16 kcal/mol) (Supplementary Fig. S7, Supplementary Table S16), which highlight the potential for drug repurposing strategies targeting CD72 in melanoma treatment. This evidence concerns the gene CD72 and melanoma.